Vol. 5 No. 8 (2025)
Reimbursement Recommendations

Crovalimab (Piasky)

decorative image of the issue cover

Published August 7, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Piasky be reimbursed by public drug plans for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents aged 13 years and older with a body weight of at least 40 kg, if certain conditions are met.
  • Piasky should only be covered to treat adults and adolescents (aged 13 years and older, weighing at least 40 kg) diagnosed with PNH, according to the reimbursement criteria used for other C5 inhibitors currently reimbursed for the treatment of PNH. Patients who are not responding as expected or the treatment failed with eculizumab or ravulizumab at the Health Canada– recommended dosage are not eligible for reimbursement of Piasky.
  • Piasky should only be prescribed at the Health Canada–recommended dosage and the cost of Piasky should not exceed the drug program cost of treatment with the least costly C5 inhibitor reimbursed for the treatment of PNH. Piasky must be prescribed by, or in consultation with, a hematologist with experience managing PNH.